234 related articles for article (PubMed ID: 30247642)
1. Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review.
van Iersel L; Brokke KE; Adan RAH; Bulthuis LCM; van den Akker ELT; van Santen HM
Endocr Rev; 2019 Feb; 40(1):193-235. PubMed ID: 30247642
[TBL] [Abstract][Full Text] [Related]
2. Management of Hypothalamic Obesity.
Müller HL
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):533-552. PubMed ID: 32741487
[TBL] [Abstract][Full Text] [Related]
3. Approach to the Patient With Hypothalamic Obesity.
Shoemaker AH; Tamaroff J
J Clin Endocrinol Metab; 2023 Apr; 108(5):1236-1242. PubMed ID: 36413492
[TBL] [Abstract][Full Text] [Related]
4. The development of hypothalamic obesity in craniopharyngioma patients: A risk factor analysis in a well-defined cohort.
van Iersel L; Meijneke RWH; Schouten-van Meeteren AYN; Reneman L; de Win MM; van Trotsenburg ASP; Bisschop PH; Finken MJJ; Vandertop WP; van Furth WR; van Santen HM
Pediatr Blood Cancer; 2018 May; 65(5):e26911. PubMed ID: 29314661
[TBL] [Abstract][Full Text] [Related]
5. Acquired hypothalamic obesity: A clinical overview and update.
Roth CL; McCormack SE
Diabetes Obes Metab; 2024 Apr; 26 Suppl 2():34-45. PubMed ID: 38450938
[TBL] [Abstract][Full Text] [Related]
6. Interventions for the Treatment of Craniopharyngioma-Related Hypothalamic Obesity: A Systematic Review.
Ni W; Shi X
World Neurosurg; 2018 Oct; 118():e59-e71. PubMed ID: 29945001
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Hypothalamic Obesity in Patients With Adult-Onset Craniopharyngioma: A Consecutive Series of 120 Cases.
Wu W; Sun Q; Zhu X; Xiang B; Zhang Q; Miao Q; Wang Y; Li Y; Ye H
Front Endocrinol (Lausanne); 2021; 12():694213. PubMed ID: 34394000
[TBL] [Abstract][Full Text] [Related]
8. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy.
Inge TH; Pfluger P; Zeller M; Rose SR; Burget L; Sundararajan S; Daniels SR; Tschöp MH
Nat Clin Pract Endocrinol Metab; 2007 Aug; 3(8):606-9. PubMed ID: 17643131
[TBL] [Abstract][Full Text] [Related]
9. Effects of T3 treatment on brown adipose tissue and energy expenditure in a patient with craniopharyngioma and hypothalamic obesity.
van Santen HM; Schouten-Meeteren AY; Serlie M; Meijneke RW; van Trotsenburg AS; Verberne H; Holleman F; Fliers E
J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):53-7. PubMed ID: 25514327
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Acquired Hypothalamic Obesity: Now and the Future.
Dimitri P
Front Endocrinol (Lausanne); 2022; 13():846880. PubMed ID: 35464063
[TBL] [Abstract][Full Text] [Related]
11. Craniopharyngioma treatment: an updated summary of important clinicopathological concepts.
Prieto R; Rosdolsky M; Hofecker V; Barrios L; Pascual JM
Expert Rev Endocrinol Metab; 2020 Jul; 15(4):261-282. PubMed ID: 32615875
[TBL] [Abstract][Full Text] [Related]
12. Hypothalamic obesity in children.
Bereket A; Kiess W; Lustig RH; Muller HL; Goldstone AP; Weiss R; Yavuz Y; Hochberg Z
Obes Rev; 2012 Sep; 13(9):780-98. PubMed ID: 22577758
[TBL] [Abstract][Full Text] [Related]
13. Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection.
Hsu EA; Miller JL; Perez FA; Roth CL
J Clin Endocrinol Metab; 2018 Feb; 103(2):370-375. PubMed ID: 29220529
[TBL] [Abstract][Full Text] [Related]
14. Management of hypothalamic disease in patients with craniopharyngioma.
Thompson CJ; Costello RW; Crowley RK
Clin Endocrinol (Oxf); 2019 Apr; 90(4):506-516. PubMed ID: 30614015
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon.
Roth CL; Zenno A
Front Endocrinol (Lausanne); 2023; 14():1256514. PubMed ID: 37780616
[TBL] [Abstract][Full Text] [Related]
16. The infundibulo-tuberal syndrome caused by craniopharyngiomas: clinicopathological evidence from an historical French cohort (1705-1973).
Castro-Dufourny I; Carrasco R; Prieto R; Barrios L; Pascual JM
Pituitary; 2015 Oct; 18(5):642-57. PubMed ID: 25527245
[TBL] [Abstract][Full Text] [Related]
17. Hypothalamic obesity.
Hochberg I; Hochberg Z
Endocr Dev; 2010; 17():185-196. PubMed ID: 19955767
[TBL] [Abstract][Full Text] [Related]
18. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity.
Roth CL; Eslamy H; Werny D; Elfers C; Shaffer ML; Pihoker C; Ojemann J; Dobyns WB
Obesity (Silver Spring); 2015 Jun; 23(6):1226-33. PubMed ID: 25884561
[TBL] [Abstract][Full Text] [Related]
19. Hypothalamic obesity.
Babcock Gilbert S; Roth LW
Minerva Endocrinol; 2015 Mar; 40(1):61-70. PubMed ID: 25370939
[TBL] [Abstract][Full Text] [Related]
20. Postoperative hypothalamic damage predicts postoperative weight gain in patients with adult-onset craniopharyngioma.
Wu J; Fu J; Huang ZJ; Xie SH; Tang B; Wu X; Tong ZG; Wu BW; Pan CB; Yang YQ; Ding H; Li SY; Qi JL; Hong T
Obesity (Silver Spring); 2022 Jul; 30(7):1357-1369. PubMed ID: 35707874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
